A. Stopeck - Concepedia

Author

A. Stopeck

University of Arizona Cancer Center

Also Known As

A Stopeck, A. Stopeck, A. T. Stopeck, A.T. Stopeck, AT Stopeck

Publications

414

Citations

H-Index

Concepts

All Affiliations

University of Arizona Cancer Center Cleveland Clinic Eon Corporation (United States)University of Arizona

About

A. Stopeck is an author at University of Arizona Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	379
2	Pathology	6	6	286
3	Health Sciences	5	5	148
4	Immunology	5	5	143
5	Cell Biology	3	3	215

A. Stopeck

Publications

379

Citations

H-Index

Page 1

	Year	Citations
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases W. Jeffrey Allard, Jeri Matera, Michael Craig Miller, Journal of Clinical Oncology Healthy SubjectsOncologic ImagingBlood CellPathologyPeripheral Blood	2004	164
Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) Shanu Modi, S. Sugarman, A. Stopeck, Journal of Clinical Oncology Breast OncologyImmunologyHsp90 Inhibitor TanespimycinPharmacotherapyImmunotherapy	2008	62
Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin’s lymphoma (NHL): Southwest Oncology Group Study S0108 A. Stopeck, William Bellamy, Joseph M. Unger, Journal of Clinical Oncology Aggressive Nhl SpecimensImmunologyPathologyPharmacotherapyImmunotherapy	2005	39
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases W. Jeffrey Allard, Jeri Matera, Michael Craig Miller, Journal of Clinical Oncology Healthy SubjectsOncologic ImagingBlood CellPathologyPeripheral Blood	2004	38
A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC) Hope S. Rugo, Sandra Franco, P.N. Munster, Journal of Clinical Oncology Breast OncologyCardiovascular PharmacologyPathologyPharmacotherapyCardiovascular Toxicity	2008	19
Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T) Shanu Modi, A. Stopeck, Michael S. Gordon, Journal of Clinical Oncology Breast OncologyHer2 Status UnknownImmunologyPharmacotherapyTumor Biology	2006	16
P3-16-07: Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study. A. Stopeck, Allan Lipton, Miguel Martín, Cancer Research Zoledronic AcidBreast OncologyOncologyCancer ManagementMetronomic Therapy	2011	15
Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis Massimo Cristofanilli, G. T. Budd, Matthew J. Ellis, Journal of Clinical Oncology Breast OncologyCancer ManagementImmunologyPathologyCancer Biology	2005	13
Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC) G. T. Budd, Massimo Cristofanilli, Matthew J. Ellis, Journal of Clinical Oncology Breast OncologyOncologic ImagingCancer ManagementImmunologyPathology	2005	13

Page 1